PositiveID ExcitePCR Aims to Launch Two Versions of POC MDx Platform Over Next Two Years Premium ExcitePCR's technology detects pathogens in 30 minutes or less using a backpack-sized device, integrating sample prep with PCR and RIF technology in a disposable cartridge. PositiveID Forms Subsidiary to Develop PCR-Based Pathogen Detection System The subsidiary, called ExcitePCR, will own and complete development of the company's Firefly Dx real-time PCR breadboard prototype pathogen detection system. In Brief This Week: Qiagen; DiaSorin; Quest; Agilent; Thermo Fisher Scientific; and More Qiagen has extended the offer period for its DKK683 million ($103.5 million) acquisition of Exiqon. PositiveID 2015 Revenues Balloon on License Fee, Recent Acquisitions The company's revenues were primarily derived from a deferred license fee from Boeing, with the remainder coming from the operations of two recent acquisitions. PositiveID Inks Deal for $2.4M in Financing Proceeds will go toward the further development and field testing of the Firefly DX system and for general working capital. Aug 4, 2015 PositiveID, GenArraytion Partner to Test Pathogen Detection Dx Assays Feb 5, 2015 PositiveID Guides to $3M-$6M in Revenues for 2015 Nov 26, 2014 PositiveID to Issue $4M in Senior Notes to Investor Nov 6, 2014 PositiveID Collaborates With US Military to Further Develop Handheld Real-time PCR Device Oct 10, 2014 PositiveID, Ensco Win DHS Biothreat Detection Contract Jun 6, 2014 In Brief This Week: Agilent Technologies; Diagnocure; KineMed, Pfizer; PositiveID; SomaLogic May 15, 2014 PositiveID Developing Handheld PCR for Space, Biodefense with Eye Toward Clinical Apps Premium May 5, 2014 PositiveID Inks Space Act Agreement with NASA to Develop Firefly Dx Apr 24, 2014 PositiveID to Use PCR Technology as Part of Shared Defense Contract with Leidos Mar 31, 2014 PositiveID Wins Contract to Support Biothreat Detection Research May 2, 2013 PositiveID Developing Handheld Version of Cassette-based MDx Platform Premium Apr 22, 2013 PositiveID Board Approves 1-for-25 Reverse Stock Split Nov 6, 2012 PositiveID, SAIC Team Up in Pursuit of Defense Threat Reduction Contracts May 14, 2012 PositiveID Subsidiary Partners with U. of Nevada for Radiation Detection Technology Mar 29, 2012 MicroFluidic Systems Seeks Clinical Partners after Winning Key IP for MDx Cartridge Tech Premium Dec 8, 2011 People in the News: Leroy Hood Joins PrimeraDx SAB; TrovaGene Names New CEO Premium Dec 7, 2011 IP Watch: Roche, Rubicon, NuGen, Alere, Merck, Gen-Probe, Intel, and Others Win US Patents Premium Aug 3, 2011 IP Watch: Recent Patents Related to PCR, Nucleic Acid Amplification, and Sample Prep: Aug 3, 2011 Premium Jul 20, 2011 PositiveID Wins WIPO Patent Covering Microfluidic Sample Prep Tech Premium May 19, 2011 PositiveID Acquires MFSI to Bring Sample Prep, MDx Tech to Biodefense, Clinical Markets Premium Load More Breaking News Sequencing Study Uncovers MERS-Related Coronavirus in Swiss Bats Angstrom Bio Raises $3M in Private Financing Eagle Biosciences, Genetic Analysis Ink Distribution Agreement for Gut Microbiota Test Centogene Q1 Revenues Grow More Than Fivefold Driven by COVID-19 Testing Epizyme Partnering With Quest Diagnostics for Lymphoma Mutation Testing Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel The Scan CDC Calls Delta "Variant of Concern" CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern." From FDA to Venture Capital Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post. Consent Questions Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles. Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.